Supplementary Table 4. Clopidogrel-aspirin versus aspirin on clinical outcome in patients included in this study

Outcome	Total (n=4,693)	Aspirin (n=2,373)	Clopidogrel-aspirin (n=2,320)	HR or RR* (95% CI)	*P*	Adjusted HR or RR*‖ (95% CI)	Adjusted *P*‖
Primary efficacy outcome							
Stroke, including ischemic and hemorrhagic stroke	357 (7.6)	199 (8.4)	158 (6.8)	0.80 (0.65–0.99)	0.04	0.81 (0.66–1.00)	0.05
Secondary efficacy outcome							
Composite events†	363 (7.7)	202 (8.5)	161 (6.9)	0.81 (0.66–0.99)	0.04	0.81 (0.66–1.00)	0.05
Ischemic stroke	344 (7.3)	195 (8.2)	149 (6.4)	0.77 (0.62–0.96)	0.02	0.78 (0.63–0.96)	0.02
Recurrent stroke	262 (5.6)	143 (6.0)	119 (5.1)	0.84 (0.66–1.07)	0.16	0.84 (0.66–1.08)	0.17
Poor functional outcome‡	460 (9.8)	262 (11.1)	198 (8.5)	0.77 (0.64–0.93)	<0.01	0.78 (0.64–0.93)	<0.01
Primary safety outcome							
Moderate to severe bleeding§	27 (0.6)	10 (0.4)	17 (0.7)	1.74 (0.80–3.80)	0.16	1.74 (0.80–3.81)	0.16
Secondary safety outcome							
Death from any cause	45 (1.0)	20 (0.8)	25 (1.1)	1.28 (0.71–2.31)	0.41	1.29 (0.72–2.33)	0.39
Any bleeding§	107 (2.3)	47 (2.0)	60 (2.6)	1.31 (0.89–1.91)	0.17	1.32 (0.90–1.94)	0.15

Values are presented as n (%) unless otherwise indicated.
HR, hazard ratio; RR, relative risk; CI, confidence interval.
*RRs were shown for poor functional outcomes. HRs were shown for other outcomes; †Composite event included stroke, myocardial infarction, or death from cardiovascular causes; ‡Poor functional outcome included modified Rankin Scale scores of 2 to 6. Modified Rankin Scale scores range from 0 to 6, with higher scores indicating more disability; §Bleeding events were defined in accordance with the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries criteria; ‖Adjusted for age, gender, BMI, history of hypertension, diabetes, dyslipidemia, previous ischemic stroke, and current smoking.

https://doi.org/10.5853/jos.2025.05092